- 中文名稱
Anti-Human CCL-22
- 英文名字
- Anti-Human CCL-22
- 供應商
- ReliaTech
- 產品貨號
- 101-M266
- 產品報價
- ￥詢價/100ug
- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868
- 產品新聞
- 背景資料
- CCL22, also named stimulated T cell chemotactic protein (STCP1) and MDC, is a CC chemokine initially isolated from clones of monocytederived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocytederived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV1 isolates and the T cell lineadapted isolate HIV1 IIIB, has been identified as CCL22. Based on aminoterminal sequence analysis, the major CD8 + T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.
- 應用類型
- WB, N
- 免疫原
- 該Anti-Human CCL-22的詳細信息查看ReliaTech提供的產品說明書。
- 來源宿主
- 該Anti-Human CCL-22的詳細信息查看ReliaTech提供的產品說明書。
- 反應性
- 該Anti-Human CCL-22的詳細信息查看ReliaTech提供的產品說明書。
- 保存建議
- 該Anti-Human CCL-22的詳細信息查看ReliaTech提供的產品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.
- 其他
- ReliaTech全稱為受體配體技術有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術公司。ReliaTech主要專注于受體和配體的發現與研究。此外，ReliaTech也開發應用于血管與淋巴管生成研究的相關高品質試劑。目前ReliaTech提供近2800款產品，產品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。
- 注意
-
該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。
-
